Centralized Pan-Middle East Survey on the Under-treatment of Hypercholesterolemia, Sub-study for the Gulf States

AstraZeneca1,000 enrolled

Overview

The purpose of the study is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III guidelines, overall and by country, to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III in the following sub-populations: * Primary/secondary prevention patients. * Patients with metabolic syndrome (according to NCEP III definition). And to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines/national guidelines, in the survey population and in the following sub-populations: * Primary/secondary prevention patients. * Patients with metabolic syndrome.

Study Type

OBSERVATIONAL

Enrollment

1,000

Conditions

Hypercholesterolemia

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Race * On lipid-lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks. * Subject must sign informed consent Exclusion Criteria: * Subjects who are unwilling or unable to provide informed consent.

Locations (1)

Research Site

Abu Dhabi, United Arab Emirates

Outcomes

Primary Outcomes

To establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III guidelines, overall and by country.

Time frame: 6 months- One visit only, no follow up visits.

Secondary Outcomes

Proportion patients on lipid-lowering drugs (LLD) reaching the LDL-C goals according to the NCEP ATP III/ updated 2004 NCEP ATP III in subgroups: Primary/secondary prevention patients; Patients with metabolic syndrome ( NCEP III).

Time frame: 6 months- One visit only, no follow up visits.

Proportion patients on LLD reaching the LDL-C goals according to the Third Joint European Task Force guidelines/national guidelines, in the survey population and in sub-populations: Primary/secondary prevention patients; Patients with metabolic syndrome.

Time frame: 6 months- One visit only, no follow up visits.

To identify determinants (e.g. patient and physician characteristics, country-specific guidelines or recommendations) for undertreatment of hypercholesterolemia.

Time frame: 6 months- One visit only, no follow up visits.